Cellule staminali

IWP-O1 is a highly potent Porcupine (Porcn) inhibitor (EC50: 80 pM), effectively suppresses the phosphorylation of Dvl2/3 and LRP6 in HeLa cells.

Tegatrabetan (BC2059) is a small molecule inhibitor of the Wnt/beta-catenin pathway with potential antineoplastic activity.

GS87 is a highly specific inhibitor of GSK3 (glycogen synthase kinase 3) that induces extensive differentiation of AML cells.

SH-4-54 is a most potent, small molecule, nonphosphorylated STAT3 inhibitor.

<p>2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide (GDC046), a potent lead analog, has good kinase selectivity and physicochemical properties.</p>

AZD1080 is a selective, orally active, brain permeable GSK3 inhibitor.

Teplinovivint is a potent inhibitor of the Wnt/β-catenin signaling pathway, demonstrating anti-inflammatory properties with potential utility in tendinopathy

<p>CMD178 (TFA) is a lead peptide that consistently reduces the expression of Foxp3 and STAT5 induced by IL-2/s IL-2Rα signaling.</p>

<p>iCRT 14 is a novel potent inhibitor of β-catenin-responsive transcription (CRT)(IC50= 40.3 nM in assays of Wnt pathway activity).</p>

WDR5-0103 hydrochloride[890190-22-4(free base)] (WD-Repeat Protein 5-0103) is an effective and specific WD repeat-containing protein 5 (WDR5) antagonist (Kd:

<p>KY02111 facilitates differentiation of hPSCs to cardiomyocytes by inhibiting Wnt signaling, maybe affect downstream of GSK3β and APC.</p>

<p>NCC007 is a novel CKIα and CKIδ dual inhibitors by structural modification of N9 and C2 position of longdaysin.</p>

Silmitasertib (CX-4945) is a potent, orally bioavailable inhibitor of casein kinase 2 (CK2; Ki: 0.38 nM).

JAK3-IN-6 is irreversible Janus Associated Kinase 3 (JAK3) inhibitor, with an IC50 of 0.15 nM

β-catenin-IN-2 is a potent inhibitor of β-catenin that can be used in colorectal cancer research.

<p>Afuresertib hydrochloride is an inhibitor of Akt kinase (Kis of 0.08/2/2.6 nM for Akt1/Akt2/Akt3 respectively)</p>

TTP 22: ATP-competitive CK2 inhibitor; IC50/Ki: 0.1 μM/40 nM; >250x selective over JNK3, ROCK1, MET.

<p>I3MT-3 (HMPSNE) is a selective inhibitor of 3MST, targeting active site cysteine residues and permeating cell membranes.</p>

<p>Fz7-21, a peptide antagonist of FZD7, inhibits Wnt/β-catenin signaling (IC50=50-100nM) in cells with WNT3A.</p>

AS1517499 is a blood-brain barrier permeable inhibitor of STAT6 phosphorylation (IC50= 21 nM). High-Quality, Low-Cost!

<p>exo-IWR-1 (exo-IWR 1) is an inactive stereoisomer of Endo-IWR-1,and is a negative control of IWR-1. IWR-1 is a tankyrase inhibitor which inhibits Wnt/β-catenin</p>

<p>YO-01027 (DBZ) is a potent γ-secretase inhibitor.</p>

<p>GNF4877 inhibits DYRK1A/GSK3β (IC50: 6/16 nM), blocks NFATc export, and boosts β-cell growth.</p>

WHI-P97 is a rationally designed potent inhibitor of JAK-3.

Belumosudil (Rezurock) is an orally available, and specific ROCK2 inhibitor (IC50/Ki: 60/41 nM).

(E/Z)-GSK-3β inhibitor 1 is a glycogen synthase kinase 3β (GSK-3β) inhibitor and demonstrates high antidiabetic efficacy.

Wnt pathway activator 1 is a potent Wnt activator with an IC50 of 28-29 nM.

S3I-201 (S3I-201) is a selective Stat3 inhibitor (IC50: 86±33 μM) and low effect towards STAT1/5.

IHR-1, a Smo inhibitor (IC50 7.6 nM), blocks Hedgehog pathway, not Wnt/Notch, and prevents Smo in primary cilium.

Avagacestat (BMS-708163) (BMS-708163) is a potent, selective, orally bioavailable γ-secretase inhibitor of Aβ40 and Aβ42 with IC50 of 0.3 nM and 0.27 nM,

MRT-14 is a potent Smo antagonist and can be used in several types of cancers linked to abnormal Hh signaling studies.

BDP5290 is a potent inhibitor of both ROCK and MRCK(IC50s of 5 nM, 50 nM, 10 nM and 100 nM for ROCK1, ROCK2, MRCKα and MRCKβ, respectively.)

Lats-IN-1 is a potent and ATP-competitive Lats1 and Lats2 kinases inhibitor. It promotes Yap-dependent proliferation in postmitotic mammalian tissues.

LY3200882 is a highly selective inhibitor of TGF-β receptor type 1 (TGFβRI).

WAY 316606 is an inhibitor of the secreted protein sFRP-1, an endogenous antagonist of the secreted glycoprotein Wnt.

<p>XMU-MP-1 is a reversible and selective MST1/2 kinase inhibitor, IC50 values for MST1 and MST2 are 71.1 nM and 38.1 nM, respectively. High-Quality, Low-Cost!</p>

Crenigacestat (LY3039478) is an orally bioavailable Notch inhibitor with an IC50 of ~1 nM in most of the tumor cell lines tested.

Fosciclopirox (CPX-POM), the phosphoryloxymethyl ester of CPX (Ciclopirox Prodrug, CPX-POM), selectively delivers the active metabolite, CPX, to the entire

Jagged-1 (188-204) TFA, a JAG-1 skin protein fragment, induces epidermal maturation and keratinocyte stratification.

SKL2001, an agonist of the Wnt/β-catenin pathway, can disrupt the Axin/β-catenin interaction.

<p>AR-A014418 (GSK 3β inhibitor VIII) is an ATP-competitive, and selective GSK3β inhibitor.</p>

KYA1797K is a highly potent and selective inhibitor. Wnt/β-catenin IC50 is 0.75 μM through TOPflash assay.

AZD2858 is a selective GSK-3 inhibitor, inhibiting tau phosphorylation at the S396 site and activating Wnt signaling pathway.

SB 216763 (SB216763) is an effective and specific GSK-3α/β inhibitor (IC50: 34.3 nM).

<p>JANEX-1: cell-permeable, reversible Jak3 inhibitor (IC50: 78 μM), ATP-competitive, selective; weak on JAK1/2, Zap/Syk, SRC.</p>

Pyrvinium pamoate (Pyrvinium embonate) is an old anthelminthic medicine for the treatment of enterobiasis , which re-attracts attention as an anti-cancer drug

KY19382, a dual CXXC5-DVL and GSK3β inhibitor (IC50s: 19/10 nM), boosts Wnt/β-catenin signaling and may help in metabolic disease research.

MYF-01-37 (1-[3-Methyl-3-[3-(trifluoromethyl)anilino]pyrrolidin-1-yl]prop-2-en-1-one) is a novel covalent TEAD inhibitor.

CKI-7 is a potent and ATP-competitive inhibitor of casein kinase 1 (CK1; IC50: 6 μM; Ki: 8.5 μM) and a selective Cdc7 kinase inhibitor.

<p>CP21 is a specific GSK3β inhibitor, used to activate stem cells for differentiation, often paired with BMP4 for mesodermal fate.</p>

Upadacitinib (ABT-494), a selective JAK1 inhibitor, is researched for autoimmune diseases; IC50: 43 nM.

BD750 is an effective immunosuppressant and a JAK3/STAT5 inhibitor, inhibits IL-2-induced JAK3/STAT5-dependent T cell proliferation(IC50 of 1.5 μM and 1.1 μM in

VP3.15 dihydrobromide: potent, oral, CNS-penetrant PDE7/GSK3 inhibitor; IC50s: PDE7- 1.59 μM, GSK- 0.88 μM.

LGK974 (NVP-LGK974) is a selective PORCN inhibitor that blocks Wnt signaling, used in metastatic colorectal and head/neck cancer trials. IC50: 0.4 nM.

<p>View and buy Y-27632 dihydrochloride from TargetMol.Y-27632 is a selective inhibitor of ROCKs.Cited in 10 publications.</p>

Cardiogenol C hydrochloride (Cardiogenol C) can induces the differentiation of ESCs into cardiomyocytes (EC50= 100 nM).

<p>(E/Z)-GO289, which strongly lengthened circadian period, is a potent and selective inhibitor of CK2.</p>

CEP-33779 is a novel and selective inhibitor of JAK2 with an IC50 of 1.8±0.6 nM.

WHI-P97 HCl is a potent and selective JAK-3 inhibitor.

SJ000291942 is an activator of the canonical bone morphogenetic proteins (BMP) signaling pathway.

IWP-2 is a Wnt pathway inhibitor and an ATP-competitive CK1δ inhibitor. IWP-2 inhibits self-renewal of embryonic stem cells. Cost effective and quality assured.

<p>Indirubin-3′-oxime is an effective inhibitor of cyclin-dependent protein kinases, and may play an obligate role in neuronal apoptosis in Alzheimer's disease.</p>

<p>Abrocitinib (PF-04965842) (PF-04965842) is a potent, specific and orally-active JAK1 inhibitor (IC50s: 29/803 nM for JAK1/2).</p>

RKI1313 (RKI-1313) was a selective inhibitor for ROCK-dependent signaling, cytoskeletal changes, anchorage-independent colony formation, migration, and invasion

LF3 is a specific inhibitor of canonical Wnt signaling by disrupting the interaction between β-catenin and TCF4 (IC50 < 2 μM)

LSKL, Inhibitor of Thrombospondin TSP-1 acetate is activation of TGF-β .

<p>Fasudil hydrochloride (HA-1077) is a potent inhibitor of ROCK1, PKA, PKC, and MLCK with Ki of 0.33 μM, 1.0 μM, 9.3 μM and 55 μM, respectively.</p>

Kartogenin (KGN) is an activator of the smad4/smad5 pathway, and promotes the selective differentiation of multipotent mesenchymal stem cells into chondrocytes.

<p>TBB (NSC-231634)(NSC-231634) is a highly selective, ATP/GTP-competitive inhibitor of casein kinase-2 (CK2).</p>

<p>Itacitinib (INCB039110) is an orally bioavailable inhibitor of Janus-associated kinase 1 (JAK1) with potential antineoplastic activity.</p>

<p>IWP L6 (Porcn Inhibitor III) is an extremely effective Porcn inhibitor (EC50: 0.5 nM).</p>

PF-4800567 is a selective inhibitor of casein kinase 1ε (CK1ε; IC50 = 32 nM) with greater than 20-fold selectivity over CK1δ.

ETC-159 (ETC-1922159) is a potent, orally available PORCN inhibitor. It inhibits β-catenin reporter activity with an IC50 of 2.9 nM.

<p>BML-284 hydrochloride (Wnt agonist 1 HCL) is a potent, selective Wnt canonical signaling activator and tubulin polymerization inhibitor.</p>

LH846 is a selective inhibitor of CK1δ (IC50 values are 290 nM, 1.3 uM and 2.5 uM for CK1δ, ε and α); exhibits no inhibitory activity at CK2.

Stafia-1 is a potent STAT5a inhibitor ( IC50=22.2 μM). Stafia-1 displays high selectivity over STAT5b and other STAT family members.

MSAB inhibits Wnt/β-catenin by binding to β-catenin and inducing its breakdown.

<p>WAY262611 is a Wnt/β-catenin agonist and an inhibitor of Dkk1. It increases bone formation rate with EC50 of 0.63 μM in TCF-luciferase assay.</p>

PF-04802367 is a highly selective GSK-3 inhibitor with an IC50 of 2.1 nM based on a recombinant human GSK-3β enzyme assay and 1.1 nM based on ADP-Glo assay.

<p>Solcitinib (GLPG-0778), a JAK1 inhibitor, may treat psoriasis, ulcerative colitis, and lupus.</p>

TED-347 is an irreversible and covalent inhibitor of TEAD4-Yap1 protein-protein interaction(EC50 of 5.9 μM), and inhibits glioblastoma cell viability.

<p>SD-208 (ALK5 Inhibitor V), a selective TGF-βRI (ALK5) inhibitor (IC50: 48 nM), is &gt;100-fold selectivity over TGF-βRII.</p>

Fosifidancitinib is a potent inhibitor of JAK 1 and JAK 3.

PF-5274857: selective hedgehog pathway inhibitor (IC50: 5.8 nM, Ki: 4.6 nM), treats brain tumors, crosses blood-brain barrier, orally stable.

SRI-011381, a new-type agonist of the TGF-beta signaling pathway, is utilized in the treatment of Alzheimer's disease.

IWP-4 (Inhibitor of Wnt Production-4) is a potent Wnt inhibitor.

GSK269962A (GSK269962A HCl) is a selective ROCK(Rho-associated protein kinase) inhibitor with IC50 values of 1.6 and 4 nM for ROCK1 and ROCK2, respectively.

<p>Oclacitinib (PF-03394197)(PF03394197) is a potent and selective JAKs inhibitor with IC50 of 10-99 nM; not inhibit a panel of 38 non-JAK kinases (IC50 's &gt; 1000</p>

<p>AZD1480: JAK2 inhibitor, IC50 0.26 nM; selective vs Tyk2, JAK3; less on JAK1. Used in solid tumors, PPV, PMF, ET trials.</p>

JAK-IN-5 hydrochloride is a JAK inhibitor [1].

Netarsudil mesylate (AR-13324 mesylate) is a Rho-related protein kinase inhibitor used to study glaucoma and hypertension.

CHIR 98024: strong GSK-3α/β blocker, IC50 0.65/0.58 nM, selective over Cdc2/ERK2.

<p>PRI-724 is a second-generation, selective small molecule inhibitor of the β-catenin/CBP interaction.Cost-effective and quality-assured.</p>

<p>GS-829845 is a JAK1 inhibitor, the main component of the active metabolite of Filgotinib, which is approximately 10-fold less potent and has a longer half-life</p>

Potent oral TEAD-YAP/TAZ inhibitor-2 with 3 nM EC50; exhibits anti-proliferative and antitumor effects.

RO7185876 is a selective gamma secretase modulator, which can be used in the study of Alzheimer's disease.

The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Human Cys-C, and the Human Cys-C standard plate wells that pre-coated using protein-related techniques are provided separately. Standard/Sample Diluent Buffer or samples are added to the appropriate microtiter plate wells ,then added a HRP-conjugated antibody specific to Human Cys-C. After TMB substrate solution is added, only those wells that contain Human Cys-C and HRP-conjugated antibody will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Human Cys-C in the samples is then determined by comparing the OD of the samples to the standard curve.

VT107 is a potent pan-TEAD autopalmitoylation inhibitor. VT-107 can be used in cancer therapy research.Cost-effective and quality-assured.

Nisevokitug (anti-TGF-β mAb) neutralizes TGF-β and is being studied for its ability to modulate the immunosuppressive tumor microenvironment.

Livmoniplimab (ABBV-151; ARGX-115) is a humanised monoclonal antibody targeting LRRC32 (GARP)/TGFβ1, which blocks TGFβ1 release mediated by LRRC32